Owkin awarded for its use of AI to diagnose and treat cancer
Owkin, a French-American startup that uses artificial intelligence and Federated Learning for medical research, has been named the most disruptive company using AI to optimize and discover new cancer treatments at the MedTech Visionaries Awards.
Receiving the award for Best MedTech Company in the Field of Oncology AI for Precision Medicine, Owkin co-founder and clinical research doctor Thomas Clozel MD said that the award reflects how “speed and collaboration” have never been more important in medical research.
“Artificial intelligence is revolutionising how we diagnose and treat some of the most complex and intractable diseases. At Owkin, we use AI and Federated Learning technologies to get the upper hand in our millenia-old battle against cancer. By leaving patient data on-site, we enable researchers to collaborate at unprecedented speed while retaining data privacy – a crucial yet until now insurmountable obstacle to rapid, effective research”, said Thomas.
Owkin was co-founded by Thomas and Gilles Wainrib PhD, an academic pioneer in the field of artificial intelligence in biology, in 2016. The company’s mission is to connect the global healthcare industry through the safe and responsible use of data and application of artificial intelligence for faster and more effective research and drug development.
Using Federated Learning, an advanced form of AI that preserves data and patient privacy by leaving all data on-site in hospitals and research centres, Owkin enables partners to unlock siloed datasets while protecting patient privacy and securing proprietary data. This allows partners to access unprecedented collaboration to improve patient outcomes.
The second annual MedTech Visionaries Awards showcase the most disruptive and innovative companies using technology to improve the way patients are treated. Hosted by the creative strategists Light4Soul and sponsored by Boost Awards. The MVA’s judges selected Owkin as the 2021 winner of the Best MedTech Company in the Field of Oncology AI for Precision Medicine.
Visit Owkin’s virtual booth at medtechvisionaries.com/Owkin to learn more.
Owkin is a French-American startup that specializes in AI and Federated Learning for medical research. The multidisciplinary team of 145 people has expertise in analyzing real-world data and experience in leveraging advanced machine learning technologies on multimodal cohorts. It was co-founded in 2016 by Dr. Thomas Clozel M.D., a clinical research doctor and former assistant professor in clinical hematology, and Dr. Gilles Wainrib Ph.D., a pioneer in the field of artificial intelligence in biology. Owkin has recently published groundbreaking research at the frontier of AI and medicine in Nature Medicine, Hepatology, and Nature Communications.
Owkin leverages life science and machine learning expertise to make drug development and clinical trial design more targeted and cost-effective. Owkin applies its cutting-edge machine learning algorithms across a broad network of academic medical centers, creating dynamic models that can not only predict disease evolution and treatment outcomes, but also be used in clinical trials for enhanced analysis, high-value subgroup identification, identification of novel biomarkers, and the creation of both synthetic control arms and surrogate endpoints. The end result is better treatments for patients, developed faster, and at a lower cost.
Owkin is a lead partner in the MELLODDY project, an IMI funded consortium of 10 pharmaceutical companies and seven technical partners. Owkin’s Federated Learning technology helped create the world’s first secure predictive modeling platform to facilitate ‘co-opetive’ drug discovery at scale between competitive industrial partners.
About Light4Soul: Light4Soul has been the go-to name for developing, hosting and maintaining websites for more than two decades. Internationally respected and recognized for design and brand awareness projects we work with your team or for your sole proprietorship to exceed your goals on-time and on-budget.